

Ref.: NLL/CS/2024- 404

September 06, 2024

**To**

1. National Stock Exchange of India Limited  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai 400 051

**Symbol: NECLIFE**

2. BSE Limited  
Corporate Relationship Department,  
P J Towers, Dalal Street,  
Mumbai 400 001

**Scrip Code: 532649**

**Ref.: NSE Letter No. NSE/CM/Surveillance/14697  
dated September 05, 2024**

**Ref.: BSE Email No.  
L/SURV/ONL/PV/AA/2024-2025/197  
dated September 06, 2024**

**Sub: Increase in Volume**

Dear Sir/ Madam

This is with reference your captioned letters regarding the cited subject.

In this regard, we would like to confirm that there is no such announcement or price sensitive information which is pending to be intimated / furnished by the Company to the Stock Exchanges concerning the operations / performance of the Company.

It seems that the increase in volume / price of Equity shares of the Company is purely market driven.

We wish to iterate and clarify that all information furnished by the Company is on the public domain and that the Company will comply with the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("LODR Regulations") and keep the Stock Exchanges duly informed of all the price sensitive/ material information(s) as per LODR Regulations.

You are requested to take the above clarification on record. This is for your information and record please.

Thanking you,

Yours faithfully,  
For **Nectar Lifesciences Limited**

(Neha Vaishnav)

**Company Secretary & Compliance Officer**

## **About Nectar Lifesciences Limited:**

Nectar Lifesciences Ltd. (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. NLL has today emerged as top ranked organization amongst mid-sized pharmaceutical companies in India as per “Fortune Next 500” 2017 & is among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per “Bio-Spectrum Asia Pacific” 2016 besides being one of the top amongst Indian API manufacturers.

NLL has transformed itself from being a domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. NLL currently has a strong hold of API & Formulation business in almost 45 countries of the world, with 11 State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels. NLL is a public listed company with stocks being traded on BSE and NSE.